SCHEMBL81339

SCHEMBL81339

OCc1ccc(O)c(C(F)(F)F)c1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KIF11 P52732 1/20 0.49
HSD17B1 P14061 2/20 0.41
HSD17B2 P37059 2/20 0.41
CYP19A1 P11511 1/20 0.41
TTR P02766 1/20 0.38
PDK2 Q15119 1/20 0.38
KDM4E B2RXH2 1/20 0.38
ALDH1A1 P00352 1/20 0.38
ALOX5 P09917 1/20 0.38
GAA P10253 1/20 0.38
MAPT P10636 1/20 0.38
BACE1 P56817 1/20 0.38
IDO1 P14902 2/20 0.37
AR P10275 1/20 0.37
CA1 P00915 1/20 0.37
CA2 P00918 1/20 0.37
CA4 P22748 1/20 0.37
CA6 P23280 1/20 0.37
HSD17B10 Q99714 1/20 0.36
APP P05067 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29485598 0.85 CA1 (0.54) KIF11HSD17B1HSD17B2CYP19A1KDM4E
SCHEMBL14421293 0.85 CA1 (0.54) KIF11HSD17B1HSD17B2CYP19A1KDM4E
SCHEMBL6813477 0.84 KDM4E (0.59) KIF11HSD17B1HSD17B2CYP19A1PDK2
SCHEMBL14421294 0.83 CA1 (0.52) KIF11HSD17B1HSD17B2CYP19A1KDM4E
SCHEMBL20376284 0.83 KIF11 (0.53) KIF11CYP19A1TTRPDK2KDM4E
SCHEMBL1994099 0.83 KIF11 (0.56) KIF11PDK2IDO1ARS1PR1
SCHEMBL30368288 0.83 KIF11 (0.56) KIF11PDK2IDO1ARS1PR1
SCHEMBL17058715 0.82 CA1 (0.42) KIF11HSD17B1HSD17B2CYP19A1KDM4E
SCHEMBL8255468 0.82 LOXL2 (0.43) KIF11HSD17B1HSD17B2CYP19A1KDM4E
SCHEMBL13815294 0.82 HSD17B1 (0.40) KIF11HSD17B1HSD17B2CYP19A1TTR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025090792-A1 AMIDE PRODRUGS AND USES THEREOF AUTOBAHN THERAPEUTICS, INC. (US) 2025-05-01 WO disclosed
US-20230416460-A1 COMPOUND, RESIN COMPOSITION, RESIN SHEET, RESIN CURED PRODUCT, AND LAMINATED SUBSTRATE TDK CORPORATION (JP) 2023-12-28 US disclosed
CN-116490355-A Compound, resin composition, resin sheet, resin cured product, and laminated substrate TDK株式会社 2023-07-25 CN disclosed
WO-2022209495-A1 COMPOUND, RESIN COMPOSITION, RESIN SHEET, RESIN CURED OBJECT, AND LAMINATED SUBSTRATE TDK株式会社 2022-10-06 WO disclosed
EP-3819285-B1 4-ALKOXY-3-(TRIFLUOROMETHYL)BENZYL ALCOHOL PRODUCTION METHOD MITSUBISHI TANABE PHARMA CORP (JP) 2022-06-08 EP disclosed
EP-3492448-B1 4-ALKOXY-3-(TRIFLUOROMETHYL)BENZYL ALCOHOL PRODUCTION METHOD MITSUBISHI TANABE PHARMA CORP (JP) 2021-03-03 EP disclosed
US-10752575-B2 4-alkoxy-3-(trifluoromethyl)benzyl alcohol production method MITSUBISHI TANABE PHARMA CORPORATION (JP) 2020-08-25 US disclosed
US-20190161432-A1 4-ALKOXY-3-(TRIFLUOROMETHYL)BENZYL ALCOHOL PRODUCTION METHOD MITSUBISHI TANABE PHARMA CORPORATION (JP) 2019-05-30 US disclosed
EP-2168944-B1 AMINE COMPOUND AND PHARMACEUTICAL USE THEREOF MITSUBISHI TANABE PHARMA CORP (JP) 2016-05-11 EP disclosed
EP-2168944-B1 AMINE COMPOUND AND PHARMACEUTICAL USE THEREOF MITSUBISHI TANABE PHARMA CORP (JP) 2016-05-11 EP disclosed
CN-101730677-B Amine compound and pharmaceutical use thereof MITSUBISHI TANABE PHARMA CORP 2014-07-16 CN disclosed
US-8129361-B2 Amine compound and pharmaceutical use thereof MITSUBISHI TANABE PHARMA CORPORATION (JP) 2012-03-06 US disclosed
US-8129361-B2 Amine compound and pharmaceutical use thereof MITSUBISHI TANABE PHARMA CORPORATION (JP) 2012-03-06 US disclosed
US-8129361-B2 Amine compound and pharmaceutical use thereof MITSUBISHI TANABE PHARMA CORPORATION (JP) 2012-03-06 US disclosed
US-20100179216-A1 AMINE COMPOUND AND PHARMACEUTICAL USE THEREOF MITSUBISHI TANABE PHARMA CORPORATION (JP) 2010-07-15 US disclosed
US-20100179216-A1 AMINE COMPOUND AND PHARMACEUTICAL USE THEREOF MITSUBISHI TANABE PHARMA CORPORATION (JP) 2010-07-15 US disclosed
US-20100179216-A1 AMINE COMPOUND AND PHARMACEUTICAL USE THEREOF MITSUBISHI TANABE PHARMA CORPORATION (JP) 2010-07-15 US disclosed
CN-101730677-A Amine compound and pharmaceutical use thereof MITSUBISHI TANABE PHARMA CORP 2010-06-09 CN disclosed
EP-2168944-A1 AMINE COMPOUND AND PHARMACEUTICAL USE THEREOF Mitsubishi Tanabe Pharma Corporation (JP) 2010-03-31 EP disclosed
EP-2168944-A1 AMINE COMPOUND AND PHARMACEUTICAL USE THEREOF Mitsubishi Tanabe Pharma Corporation (JP) 2010-03-31 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190161432-A1 4-ALKOXY-3-(TRIFLUOROMETHYL)BENZYL ALCOHOL PRODUCTION METHOD ADH1C, ADH5, ADH1A KIF11 3972/4885HSD17B1 351/4885HSD17B2 337/4885
US-10752575-B2 4-alkoxy-3-(trifluoromethyl)benzyl alcohol production method ADH1C, ADH5, ADH1A KIF11 3972/4885HSD17B1 351/4885HSD17B2 337/4885
US-20100179216-A1 AMINE COMPOUND AND PHARMACEUTICAL USE THEREOF HLA-B, HLA-A, HLA-C KIF11 2343/4885HSD17B1 795/4885HSD17B2 682/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.